Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Champions Oncology (CSBR) Gross Profit (2016 - 2025)

Historic Gross Profit for Champions Oncology (CSBR) over the last 16 years, with Q4 2025 value amounting to $7.8 million.

  • Champions Oncology's Gross Profit rose 2824.62% to $7.8 million in Q4 2025 from the same period last year, while for Oct 2025 it was $29.3 million, marking a year-over-year increase of 2213.83%. This contributed to the annual value of $28.6 million for FY2025, which is 3758.79% up from last year.
  • Latest data reveals that Champions Oncology reported Gross Profit of $7.8 million as of Q4 2025, which was up 2824.62% from $6.0 million recorded in Q3 2025.
  • In the past 5 years, Champions Oncology's Gross Profit registered a high of $10.4 million during Q1 2025, and its lowest value of $4.2 million during Q1 2024.
  • For the 5-year period, Champions Oncology's Gross Profit averaged around $6.2 million, with its median value being $6.1 million (2021).
  • Per our database at Business Quant, Champions Oncology's Gross Profit crashed by 2753.73% in 2023 and then skyrocketed by 14992.81% in 2025.
  • Champions Oncology's Gross Profit (Quarter) stood at $6.2 million in 2021, then grew by 10.7% to $6.8 million in 2022, then decreased by 27.54% to $5.0 million in 2023, then rose by 22.32% to $6.1 million in 2024, then increased by 28.25% to $7.8 million in 2025.
  • Its Gross Profit was $7.8 million in Q4 2025, compared to $6.0 million in Q3 2025 and $5.1 million in Q2 2025.